Yan Zhang

Yan Zhang

Auto-generated profile, based on publicly available information

Yan Zhang

Department of Neurology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2024 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
XZXia Zhu
Xia Zhu
JHJi-Ye Huang
Ji-Ye Huang
WDWan-Ying Dong
Wan-Ying Dong
HTHao-Di Tang
Hao-Di Tang
SXSi Xu
Si Xu
ZZZhi Zhang
Zhi Zhang

23 August 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
XWXin-Yue Wang
Xin-Yue Wang
WJWen-Bin Jia
Wen-Bin Jia
XXXiang Xu
Xiang Xu
RCRui Chen
Rui Chen
LWLiang-Biao Wang
Liang-Biao Wang
YZYan Zhang
Yan Zhang
Chronic pain causes both physical suffering and comorbid mental symptoms such as anhedonia. However, the neural circuits and molecular mechanisms underlying these maladaptive behaviors remain elusive. Here using a mouse model, we report a pathway from vesicular glutamate transporter 3 neurons in the dorsal raphe nucleus to dopamine neurons in the ventral tegmental area (VGluT3DRN→DAVTA) wherein population-level activity in response to innocuous mechanical stimuli and sucrose consumption is inhibited by chronic neuropathic pain. Mechanistically, neuropathic pain dampens VGluT3DRN → DAVTA glutamatergic transmission and DAVTA neural excitability. VGluT3DRN → DAVTA activation alleviates neuropathic pain and comorbid anhedonia-like behavior (CAB) by releasing glutamate, which subsequently promotes DA release in the nucleus accumbens medial shell (NAcMed) and produces analgesic and anti-anhedonia effects via D2 and D1 receptors, respectively. In addition, VGluT3DRN → DAVTA inhibition produces pain-like reflexive hypersensitivity and anhedonia-like behavior in intact mice. These findings reveal a crucial role for VGluT3DRN → DAVTA → D2/D1NAcMed pathway in establishing and modulating chronic pain and CAB.

21 September 2023 in Cell Reports
Verified
Journal Article
Open access
XWXin-Yue Wang
Xin-Yue Wang
XXXiang Xu
Xiang Xu
RCRui Chen
Rui Chen
WJWen-Bin Jia
Wen-Bin Jia
PXPeng-Fei Xu
Peng-Fei Xu
YZYan Zhang
Yan Zhang
Chronic stress and chronic pain are two major predisposing factors to trigger depression. Enhanced excitatory input to the lateral habenula (LHb) has been implicated in the pathophysiology of depression. However, the contribution of inhibitory transmission remains unclear. Here, we dissect an inhibitory projection from the sensory thalamic reticular nucleus (sTRN) to the LHb, which is activated by acute aversive stimuli. However, chronic restraint stress (CRS) weakens sTRN-LHb synaptic strength, and this synaptic attenuation is indispensable for CRS-induced LHb neural hyperactivity and depression onset. Moreover, artificially inhibiting the sTRN-LHb circuit induces depressive-like behaviors in healthy mice, while enhancing this circuit relieves depression induced by both chronic stress and chronic pain. Intriguingly, neither neuropathic pain nor comorbid mechanical hypersensitivity in chronic stress is affected by this pathway. Altogether, our study demonstrates an sTRN-LHb circuit in establishing and modulating depression, thus shedding light on potential therapeutic targets for preventing or managing depression.

13 August 2022 in Therapeutic Advances in Neurological Disorders
Verified
Journal Article
Open access
WSWen Sun
Wen Sun
ZDZuowei Duan
Zuowei Duan
PXPengfei Xu
Pengfei Xu
LXLulu Xiao
Lulu Xiao
JWJinjing Wang
Jinjing Wang
HLHaiyan Liu
Haiyan Liu
Background: Whether endovascular treatment (EVT) is safe and effective for vertebrobasilar artery occlusion (VBAO) is yet incompletely understood. Two RCTs, the endovascular treatment versus standard medical treatment for vertebrobasilar artery occlusion (BEST) trail and the Basilar Artery International Cooperation Study (BASICS), concentrating on this field were recently reported. Objective: We use real-world registry data of VBAO to compare the outcome of EVT inside and outside the inclusion and exclusion criteria of the BEST and BASICS study to testify the feasibility of the selection paradigms of VBAO in these trials. Methods: Consecutive patients with VBAO receiving EVT involving 21 stroke centers were retrospectively included. The safety outcomes [3-month mortality, symptomatic intracranial hemorrhage (sICH), and effectiveness outcomes (the proportion of 3-month functional independence (mRS of 0–2) and favorable outcome (mRS of 0–3)] were compared between VBAO patients who meet or failed to meet the BEST/BASICS selection criteria for EVT. Results: Our study cohort consisted of 577 VBAO patients who underwent EVT. Of them, 446 patients had pc-ASPECTS ≧8. Successful reperfusion (mTICI 2b or 3) was achieved in 85.4% ( n = 493). There were 418 patients fulfilling the BEST criterion for EVT and 194 fulfilling the BASICS criterion. Regression analysis indicated that adherence to BEST or BASICS criterion for EVT was not independently related to most of the safety and effectiveness outcome except that adherence to BEST was significantly associated with the 3-month favorable outcome (ORBEST: 1.742, 95% CI: 1.087–2.790). However, when we put pc-ASPECTS into both criteria with a cut-off value of 8, meeting both BEST criterion plus pc-ASPECTS and BASICS criterion plus pc-ASPECTS was independently related to 3-month functional independence (ORBEST: 1.687, 95% CI: 1.077–2.644; ORBASIC: 1.653, 95% CI: 1.038–2.631) and favorable outcome (ORBEST: 2.280, 95% CI: 1.484–3.502; ORBASIC: 2.153, 95% CI: 1.372–3.378). Conclusion: Our study indicated that, based on real-world data of EVT, adherence to BEST or BASICS criterion for EVT was not independently associated with the safety and effectiveness outcome except that adherence to BEST was significantly related to the 3-month favorable outcome. However, the BEST or BASICS selection criterion and pc-ASPECTS ≧8 might be better paradigms for EVT patient selection.

24 May 2022 in Frontiers in Cellular Neuroscience
Verified
Journal Article
Open access
LWLiang-Biao Wang
Liang-Biao Wang
XSXiao-Jing Su
Xiao-Jing Su
QWQiao-Feng Wu
Qiao-Feng Wu
XXXiang Xu
Xiang Xu
XWXin-Yue Wang
Xin-Yue Wang
YZYan Zhang
Yan Zhang
The high incidence of treatment-resistant pain calls for the urgent preclinical translation of new analgesics. Understanding the behavioral readout of pain in animals is crucial for efficacy evaluation when developing novel analgesics. Mas-related G protein-coupled receptor D-positive (Mrgprd+) and transient receptor potential vanilloid 1-positive (TRPV1+) sensory neurons are two major non-overlapping subpopulations of C-fiber nociceptors. Their activation has been reported to provoke diverse nocifensive behaviors. However, what kind of behavior reliably represents subjectively conscious pain perception needs to be revisited. Here, we generated transgenic mice in which Mrgprd+ or TRPV1+ sensory neurons specifically express channelrhodopsin-2 (ChR2). Under physiological conditions, optogenetic activation of hindpaw Mrgprd+ afferents evoked reflexive behaviors (lifting, etc.), but failed to produce aversion. In contrast, TRPV1+ afferents activation evoked marked reflexive behaviors and affective responses (licking, etc.), as well as robust aversion. Under neuropathic pain conditions induced by spared nerve injury (SNI), affective behaviors and avoidance can be elicited by Mrgprd+ afferents excitation. Mechanistically, spinal cord-lateral parabrachial nucleus (lPBN) projecting neurons in superficial layers (lamina I–IIo) were activated by TRPV1+ nociceptors in naïve conditions or by Mrgprd+ nociceptors after SNI, whereas only deep spinal cord neurons were activated by Mrgprd+ nociceptors in naïve conditions. Moreover, the excitatory inputs from Mrgprd+ afferents to neurons within inner lamina II (IIi) are partially gated under normal conditions. Altogether, we conclude that optogenetic activation of the adult Mrgprd+ nociceptors drives non-pain-like reflexive behaviors via the deep spinal cord pathway under physiological conditions and drives pain-like affective behaviors via superficial spinal cord pathway under pathological conditions. The distinct spinal pathway transmitting different forms of nocifensive behaviors provides different therapeutic targets. Moreover, this study appeals to the rational evaluation of preclinical analgesic efficacy by using comprehensive and suitable behavioral assays, as well as by assessing neural activity in the two distinct pathways.

16 December 2025 in Cell Reports
Verified
Journal Article
Open access
XXXin-Xin Xia
Xin-Xin Xia
YWYu-Hao Wang
Yu-Hao Wang
XWXin-Yue Wang
Xin-Yue Wang
XLXiao-Qing Liu
Xiao-Qing Liu
WHWei Hu
Wei Hu
YZYan Zhang
Yan Zhang
Chronic pain frequently co-occurs with depression, forming a vicious cycle that mutually exacerbates both. Although the medial shell of nucleus accumbens (NAcMed) is known to modulate both pain and affective states, the distinct roles of D1- and D2-dopamine receptor-expressing medium spiny neurons (D1- and D2-MSNs) within the NAcMed, as well as their respective circuits, in chronic pain and comorbid depression remain poorly defined. We observed decreased activity in both MSN subtypes during chronic pain and comorbid depression. Notably, activation of D1-MSNs alleviated depressive-like behaviors, whereas activation of D2-MSNs produced analgesic effects. Furthermore, we identified two parallel neural circuits: the NAcMedD1-MSNs→mediodorsal thalamus pathway, which preferentially modulates depressive-like behaviors, and the NAcMedD2-MSNs→lateral hypothalamus pathway, which selectively relieves pain. These findings delineate a circuit-specific dichotomy in which NAcMedD1-MSNs and NAcMedD2-MSNs govern distinct affective and sensory dimensions of chronic pain-depression comorbidity, providing circuit-specific targets for potential treatment.